Metachronous primary lung carcinoma
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised David Luong had no recorded disclosures.View David Luong's current disclosures
Metachronous primary lung carcinoma usually refers to tumors with the same histology which are "separated in time" when there has been a disease-free interval between cancers.
Its definition has been "variably" defined in the literature and can include:
- time interval of at least 2 years or the second tumor is found in a different segment, lobe, or lung with no carcinoma in the lymphatics common to both; and there is no evidence of extrapulmonary metastasis at the time of diagnosis 1
- SEER database recommendation: 2-month period to distinguish between synchronous and metachronous multiple primaries.
- IARC suggestion: registration of synchronous tumors diagnosed in an interval of less than 6 months (or metachronous if more than 6 months) if arising in different sites
- "the latter two suggestions have been for "any" cancer and not just lung cancer"
On this page:
Average lifelong rate of developing a "new primary lung cancer" is thought to be approximately 1% and 6% per year after radical therapy for non-small-cell lung cancer and small cell lung cancer, respectively 4.
- pulmonary metastasis from original initial lung cancer
- 1. Battafarano RJ, Force SD, Meyers BF, Bell J, Guthrie TJ, Cooper JD, Patterson GA. Benefits of resection for metachronous lung cancer. (2004) The Journal of thoracic and cardiovascular surgery. 127 (3): 836-42. doi:10.1016/j.jtcvs.2003.08.055 - Pubmed
- 2. Vogt A, Schmid S, Heinimann K, Frick H, Herrmann C, Cerny T, Omlin A. Multiple primary tumours: challenges and approaches, a review. (2017) ESMO open. 2 (2): e000172. doi:10.1136/esmoopen-2017-000172 - Pubmed
- 3. Rzechonek A, Błasiak P, Muszczyńska-Bernhard B, Pawełczyk K, Pniewski G, Ornat M, Grzegrzółka J, Brzecka A. Metachronous Lung Cancer: Clinical Characteristics and Effects of Surgical Treatment. (2018) Advances in experimental medicine and biology. 1039: 9-17. doi:10.1007/5584_2017_82 - Pubmed
- 4. Loukeri AA, Kampolis CF, Ntokou A, Tsoukalas G, Syrigos K. Metachronous and synchronous primary lung cancers: diagnostic aspects, surgical treatment, and prognosis. (2015) Clinical lung cancer. 16 (1): 15-23. doi:10.1016/j.cllc.2014.07.001 - Pubmed
- 5. Lenner R, Teirstein AS, Krellenstein DJ. Metachronous cancers or late recurrences after resection of stage I lung cancer. (1999) The Annals of thoracic surgery. 67 (2): 548-9. Pubmed
- 6. Marniemi J, Parkki MG. Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo. (1975) Biochemical pharmacology. 24 (17): 1569-72. doi:10.1016/0006-2952(75)90080-5 - Pubmed
- 7. Koezuka S, Hata Y, Otsuka H, Makino T, Tochigi N, Shibuya K, Iyoda A. Metachronous second primary lung cancer surgically treated five years or more after the initial surgery. (2015) Molecular and clinical oncology. 3 (5): 1025-1028. doi:10.3892/mco.2015.594 - Pubmed